Figure 1.

Schematic diagram of the adoptive transfer of antigen-specific T-cell receptor redirecting T cells (TCR-T) and chimeric-antigen receptor redirecting T cells (CAR-T) for AML immunotherapy. Antigen-specific T-cell clones are generated from antigen-reactive T cells of healthy donors or patients and are inserted into a lentivirus vector. The lentivirus vector is transfected into the packing cells for the production of lentiviral particles. The lentiviral particle products containing desired αβ-TCR or CAR genes are then used to infect T cells (TCR-T, CAR-T). These genetically modified TCR-T or CAR-T cells are tested for effectiveness against cancers. TCR-T or CAR-T products are then expanded in vitro and infused into patients.